Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

GLP-1 medications are changing the way we approach weight loss and chronic conditions. Dr. Nima Mowzoon of UBI Telehealth ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Chilean foodtech firm NotCo says it expects to be profitable in Chile, Argentina, Colombia, and Peru in Q2, 2025.

Medications like Ozempic and Mounjaro work by mimicking naturally occurring hormones in the body, such as glucagon-like ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

GLP-1 drugs, originally for type 2 diabetes ... new lifestyle and to monitor for changes in mental health. Opinion: What's next for cybersecurity? Watch this NYC company Doctors prescribing ...

With one in eight Americans having taken a GLP-1 already — including 43% of those with diabetes and a quarter of people with heart disease — it’s time to shift our thinking on GLP-1s to ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, including Alzheimer's, but an increase in some other conditions like kidney ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...